Skip to search formSkip to main contentSkip to account menu

BIBW-2992-MA2

Known as: BIBW 2992MA2, BIBW-2992MA2, BIBW2992 MA2 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Afatinibafatinib dimaleate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients…
5501 Background: BIBW 2992 is a novel, potent, orally bioavailable irreversible inhibitor of EGFR/HER1 and HER2 receptor tyrosine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)